High failure rate for an epicardial implantable cardioverter-defibrillator lead: Implications for long-term follow-up of patients with an implantable cardioverter-defibrillator

被引:43
|
作者
Brady, PA [1 ]
Friedman, PA [1 ]
Trusty, JM [1 ]
Grice, S [1 ]
Hammill, SC [1 ]
Stanton, MS [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
10.1016/S0735-1097(97)00529-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The purpose of this study was to determine the risk of epicardial lead failure during long-term follow-up and its mode of presentation, Background. Despite the high prevalence of epicardial lead-based implantable cardioverter-defibrillators, their long-term performance is unknown, and appropriate follow-up has not been established, Methods. The study group comprised all patients in whom an epicardial lead system was implanted at the Mayo Clinic between October 31, 1984 and November 3, 1994, The number of lead fractures and leads with fluid within the insulation and the made of presentation were determined retrospectively by review of patient visits, radiographs of lead systems and data derived from formal lead testing. Results. At 4 years, the survival rate free of lead malfunction, using formal lead testing, for 160 Medtronic epicardial patches (models 6897 and 6921) was 72% compared with 92.5% for the 179 Cardiac Pacemaker, Inc. (CPI) patches (models 0040 and 0041) (p = = 0.01). In addition, five Medtronic patches in three patients had fluid within the lead insulation but no obvious fracture, No CPI patches had fluid identified within the leads. Of 330 Medtronic epicardial pace/sense leads (model 6917), the 4-year survival rate Free of lead malfunction as assessed by lead testing was 94%. In all, 18 presentations of lead malfunction were found in 17 patients (2 patients had more than one lead fracture at different times). In 11 (58%) of these presentations, the patients were asymptomatic despite the presence of obvious lead fracture. Conclusions. Epicardial lead malfunction is common on long-term follow-up, and some leads have a failure rate of 28% at 4 years. Many patients with fractured leads remain asymptomatic, despite involvement of multiple leads in some casts, Therefore, consideration should be given to regular periodic lead testing in addition to routine X-ray examination, as as symptomatic lead malfunction can present with normal chest X-ray findings. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:616 / 622
页数:7
相关论文
共 50 条
  • [41] Twiddling with an implantable cardioverter-defibrillator
    McCann, Conor J.
    Beelen, Roel
    Geelen, Peter
    ACTA CARDIOLOGICA, 2009, 64 (05) : 695 - 695
  • [42] Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome
    Sarkozy, Andrea
    Boussy, Tim
    Kourgiannides, Georgios
    Chierchia, Gian-Battista
    Richter, Sergio
    De Potter, Tom
    Geelen, Peter
    Wellens, Francis
    Spreeuwenberg, Marieke Dingena
    Brugada, Pedro
    EUROPEAN HEART JOURNAL, 2007, 28 (03) : 334 - 344
  • [43] Cardiac Sarcoidosis: Electrophysiological Outcomes on Long-Term Follow-Up and the Role of the Implantable Cardioverter-Defibrillator
    Mohsen, Amr
    Jimenez, Alejandro
    Hood, Robert E.
    Dickfeld, Timm
    Saliaris, Anastasios
    Shorofsky, Stephen
    Saba, Magdi M.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (02) : 171 - 176
  • [44] Long-Term Follow-Up of Implantable Cardioverter-Defibrillator for Secondary Prevention in Chagas' Heart Disease
    Martinelli, Martino
    de Siqueira, Sergio Freitas
    Sternick, Eduardo Back
    Rassi, Anis, Jr.
    Costa, Roberto
    Franchini Ramires, Jose Antonio
    Kalil Filho, Roberto
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (07): : 1040 - 1045
  • [45] Performance of an implantable cardioverter-defibrillator lead family
    Klampfleitner, Stefanie
    Mundel, Markus
    Schinke, Karin
    Neuberger, Hans-Ruprecht
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2023, 34 (03) : 700 - 709
  • [46] Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome
    Bonny, Aime
    Tonet, Joelci
    Fontaine, Guy
    Frank, Robert
    EUROPEAN HEART JOURNAL, 2007, 28 (22) : 2819 - 2820
  • [47] Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome:: A long-term follow-up
    Mönnig, G
    Köbe, J
    Löher, A
    Eckardt, L
    Wedekind, H
    Scheld, HH
    Haverkamp, W
    Milberg, P
    Breithardt, G
    Schulze-Bahr, E
    Böcker, D
    HEART RHYTHM, 2005, 2 (05) : 497 - 504
  • [48] Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
    Schaer, Beat
    Kuehne, Michael
    Reichlin, Tobias
    Osswald, Stefan
    Sticherling, Christian
    EUROPACE, 2016, 18 (02): : 227 - 231
  • [49] THE AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR - IMPLICATIONS FOR ANESTHETISTS
    CARR, CME
    WHITELEY, SM
    ANAESTHESIA, 1991, 46 (09) : 737 - 740
  • [50] Implantable Cardioverter-Defibrillator Lead Failure in Children and Young Adults
    Janson, Christopher M.
    Patel, Akash R.
    Bonney, William J.
    Smoots, Karen
    Shah, Maully J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (02) : 133 - 140